Date and time
2022-04-06 12.30-15.30 UTC
Zoom Details
https://snomed.zoom.us/j/8915921345?pwd=cXVsd2lPU3Rpc2FZM3JhTkROSUVpdz09
Password: 5095908349
Attendees
Apologies
Objectives
Discuss and make progress on these issues:
- Evaluation procedures 2 Observables (E2O) progress
- Social Determinants of Health Observables
- Impulsivity Observable
Discussion items
See below.
Item | Description | Owner | Notes | Action | ||
---|---|---|---|---|---|---|
1 | Welcome & apologies | Remember recording! | ||||
2 | Conflicts of interest | |||||
3 | Minutes from previous meeting | Daniel Karlsson | ||||
4 | E2O | The E2O project has produced a larger set of commonly used Evaluation procedure concepts as new concepts modeled using the Observables model (n=800+). The set was choosen from the 1000 most commonly used British primary care lab tests, excluding pure orderables. There is evidence that re-modelling the content can bring significant improvements. There is also evidence that current content is not consistently represented and is in need of work, particularly if some content will stay in the procedure hierarchy. There is still some disagreement about the requirement to represent orderables and reportables as distinct concepts, and if so, how these may be coordinated. There is still a requirement to represent "pure" orderables (e.g. panels) for which there is no current observables pattern. Two outcomes of the discussions could be:
| ||||
5 | Social Determinants of Health Observables | 2022-02-21: Presentation of Race and Gender assignment observables. Alejandro Lopez Osornio in latin america race typically is not recorded, with few exceptions. Nashar Karim patient-reported, self-assigned, where is that seen in the modeling? It is represented through Interview technique. Daniel Karlsson recording race is illegal in many European countries. 2022-03-21: Presentation of proposals for modeling of race, gender, and sex observables. For all these observables, a general pattern of role assignment was used, i.e. race is assigned for a person by an agent, e.g. the community. There was agreement in the group that this pattern was useful. For gender and sex observables, there was discussion about the relation between the two. Most agreed that sex and gender are distinct entities, where one is not a kind of the other. There are also many variants of both gender, e.g. and biological sex, e.g. fenotypic (external genitalia, hormone levels) or genotypic. Further, other standards organizaiton is doing work, paritcularly in the sex and gender area, indluing the HL7 Gender Harmony project https://confluence.hl7.org/display/VOC/The+Gender+Harmony+Project and the ISO TC 215 work on "Sex and Gender in Electronic Health Records" https://www.iso.org/standard/83431.html | ||||
6 | Impulsivity observable | Piper Allyn Ranallo | ||||
7 | Nesting in Observables | In relation to the change in modeling of primary and secondary/metastatic neoplasms, there has been a comment from Ed Cheetham about its implication for Observables concepts. I can see how this approach will model existing combined primary and metastatic disorders (as now, through role grouping but including the new pathological process role), but is it suitable for complex observables such as 2960001000004100 |Presence of direct invasion by metastatic carcinoma of lymph node in excised specimen to perilymphatic tissue (observable entity)|? This too makes reference to both metastasis and local invasion, but its definition is made up of multiple self-grouped attributes. If the current 'inheres in=carcinoma, metastatic' becomes 'inheres in=carcinoma' and 'characterizes=discontinuous metastatic spread", how will this 'work' with the existing 'characterizes=direct local invasion' pair and current cardinality rules? | ||||
8 | Next meeting | Next meeting is April 18 2022 20.00 UTC. Agenda:
|
Meeting Files
Attachments |
---|
Recordings
Previous Meetings
Content Report Table | ||||||||
---|---|---|---|---|---|---|---|---|
|
More Zoom details
Topic: Observables meeting
Time: this is a recurring meeting Meet anytime
Join from PC, Mac, Linux, iOS or Android:
https://snomed.zoom.us/j/992630241
Or Telephone:
Dial:
+46 (0) 8 4468 2488 (SE Toll)
+61 (0) 2 8015 2088 (AU Toll)
+32 (0) 2 588 4188 (BE Toll)
+1 647 558 0588 (CA Toll)
+56 41 256 0288 (CL Toll)
+420 2 2888 2388 (CZ Toll)
+45 89 88 37 88 (DK Toll)
+372 880 1188 (EE Toll)
+852 5808 6088 (HK Toll)
+353 (0) 1 691 7488 (IE Toll)
+972 (0) 3 978 6688 (IL Toll)
+370 5214 1488 (LT Toll)
+60 3 9212 1727 (MY Toll)
+356 2778 1288 (MT Toll)
+31 (0) 20 241 0288 (NL Toll)
+64 (0) 9 801 1188 (NZ Toll)
+64 (0) 4 831 8959 (NZ Toll)
+47 2396 0588 (NO Toll)
+48 22 307 3488 (PL Toll)
+351 308 804 188 (PT Toll)
+65 3158 7288 (SG Toll)
+421 233 056 888 (SK Toll)
+386 1888 8788 (SI Toll)
+34 91 198 0188 (ES Toll)
+41 (0) 31 528 0988 (CH Toll)
+44 (0) 20 3695 0088 (GB Toll)
+1 408 638 0968 (US Toll)
+1 646 876 9923 (US Toll)
+1 669 900 6833 (US Toll)
Meeting ID: 992 630 241
International numbers available: https://snomed.zoom.us/zoomconference?m=AQWV2VqAIGYWMcMapl9CoYjsaj1TVS7K